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Abstract
Objective
Tomake recommendations on the assessment and management of tics in people with Tourette
syndrome and chronic tic disorders.
Methods
A multidisciplinary panel consisting of 9 physicians, 2 psychologists, and 2 patient repre-
sentatives developed practice recommendations, integrating findings from a systematic review
and following an Institute of Medicine–compliant process to ensure transparency and patient
engagement. Recommendations were supported by structured rationales, integrating evidence
from the systematic review, related evidence, principles of care, and inferences from evidence.
Results
Forty-six recommendations were made regarding the assessment and management of tics in
individuals with Tourette syndrome and chronic tic disorders. These include counseling rec-
ommendations on the natural history of tic disorders, psychoeducation for teachers and peers,
assessment for comorbid disorders, and periodic reassessment of the need for ongoing therapy.
Treatment options should be individualized, and the choice should be the result of a collabo-
rative decision among patient, caregiver, and clinician, during which the benefits and harms of
individual treatments as well as the presence of comorbid disorders are considered. Treatment
options include watchful waiting, the Comprehensive Behavioral Intervention for Tics, and
medication; recommendations are provided on how to offer and monitor these therapies.
Recommendations on the assessment for and use of deep brain stimulation in adults with
severe, treatment-refractory tics are provided as well as suggestions for future research.
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This article presents the recommendations and suggestions for
future research of an American Academy of Neurology (AAN)
practice guideline on the treatment of tics in people with
Tourette syndrome (TS) and chronic tic disorders. The com-
plete and unabridged practice guideline is available as a data
supplement at links.lww.com/WNL/A882. A companion article
summarizes the systematic review findings and conclusions.
The AAN guideline committee convened a multidisciplinary
panel to perform a systematic review and develop guideline
recommendations, founded on the systematic review, for the
assessment and treatment of tics. This article focuses on the
guideline’s recommendations and does not include detailed
analysis of the systematic review. Readers are urged to review
the unabridged guideline for a full assessment.
The systematic review synthesizes the evidence supporting the
efficacy and harms ofmedical, behavioral, and neurostimulation
treatments for tics. The treatment of tics must be individualized
and based on collaborative decisions among patients, care-
givers, and clinicians. Many people with tic disorders have
psychiatric comorbidities, requiring clinicians to establish
treatment priorities with their patients. While neurologists are
often consulted to diagnose and treat tics, the identification and
management of comorbid disorders is of prime importance and
must be factored into management decisions. Therefore, while
the level of obligation and associated verbs (must, should, may)
state that treatments may or should be used, these recom-
mendations pertain only to the situation in which the patient
and clinician have determined that treatment is necessary and
collaboratively discussed treatment options and priorities.
The authors of the practice guideline seek to make recom-
mendations, based on evidence identified from the systematic
review, general principles of care, and related evidence, re-
garding the following questions:
1. In children and adults withTS or a chronic tic disorder, when
should clinicians and patients pursue treatment for tics?
2. In children and adults with TS or a chronic tic disorder
who require treatment for tics, how should clinicians and
patients choose between evidence-based treatment options
and determine the sequence or combinations of these
treatments?
Practice recommendations
Much more than evidence must be considered when crafting
practice recommendations. The evidence-based conclusions
from our systematic review form the foundation of the AAN
process, but other factors influence the structure of recom-
mendations. The panel developed rationale statements that
document, in a transparent manner, the deductive logic jus-
tifying each recommendation. These rationale statements
precede each recommendation. Four types of premises can be
used to support recommendations: (1) evidence-based con-
clusions from the systematic review (labeled EVID), (2)
generally accepted principles of care (PRIN), (3) strong ev-
idence from related conditions (RELA), and (4) deductive
inferences from other premises (INFER). Recommendations
must always be supported by at least one premise.
When there is sufficient evidence to support an inference for
the use of an intervention (i.e., the balance of benefits and
harms favors the intervention), the development panel assigns
one of 3 recommendation designations: A, B, or C. Each
designation corresponds to a helping verb that denotes the
level of strength of the recommendation. Level A is the
strongest recommendation level and is denoted by the use of
the verb must. These recommendations are rare because they
are based on high confidence in the evidence and require both
a high magnitude of benefit and low risk. Level B corresponds
to the verb should. Such recommendations tend to be more
common because the requirements are less stringent but still
based on the evidence and benefit–risk profile. Level C cor-
responds to the verb may. These recommendations represent
the lowest allowable recommendation level that the AAN
considers useful within the scope of clinical practice and
accommodates the highest degree of practice variation.
Non–evidence-based factors that need to be transparently and
systematically considered when formulating recommendations
include (1) the relative value of the benefit compared with the
risk, (2) the feasibility of complying with the intervention (e.g.,
the intervention’s availability), (3) the cost of the intervention,
and (4) the expected variation in patient preferences relative to
the risks, burdens, and benefits of the intervention. The panel
Supplemental Data
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NPub.org/vsmv3e
Glossary
AAN = American Academy of Neurology; ADHD = attention-deficit/hyperactivity disorder; CBD = cannabidiol; CBIT =
Comprehensive Behavioral Intervention for Tics;CBT = cognitive behavioral therapy;DBS = deep brain stimulation;DSM-5 =
Diagnostic and Statistical Manual of Mental Disorders, 5th edition; EVID = evidence-based conclusions from the systematic
review; HRT = habit reversal training; INFER = deductive inferences from other premises; OCD = obsessive-compulsive
disorder; PRIN = generally accepted principles of care; RELA = strong evidence from related conditions; THC = δ-9-
tetrahydrocannabinol; TS = Tourette syndrome; VMAT2 = vesicular monoamine transporter type 2.
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assigned levels of obligation (A, B, C, U, or R) to each rec-
ommendation by using a modified Delphi process that syn-
thesizes all previously listed factors. The opinions of the
guideline panel, with regard to the importance of each factor,
were elicited through an online questionnaire, with statistical
analysis of responses. The panel voted anonymously and in-
dependently on each recommendation in 3 rounds of online
voting. Using precisely defined rules for consensus for each
recommendation, the panel achieved consensus, revised the
recommendation, or did not carry the recommendation for-
ward. In some cases, the panel reviewed, revised, and revoted
on recommendations on the basis of public commentary and
other input during the guideline development process,
reflecting the dynamic nature of this process. Suggestions for
future research were created during guideline development.
Counseling recommendation: Natural history
of TS
Rationale
Providing information to families about the natural history
of a disorder can help inform treatment decisions (PRIN).
Tics begin in childhood and demonstrate a waxing and
waning course. Peak tic severity usually occurs between the
ages of 10 and 12 years, with many children experiencing an
improvement in tics in adolescence (RELA).1 A longitudinal
study demonstrated that tic severity declined yearly during
adolescence, with 18% of adolescents older than 16 years
having no tics and 60% having minimal or mild tics 6 years
after initial examination (RELA).2 There is no evidence that
treatment is more effective the earlier it is started. As tics may
improve with time, watchful waiting is an acceptable ap-
proach in individuals who do not experience any functional
impairment from their tics (INFER). However, even in such
cases, the Comprehensive Behavioral Intervention for Tics
(CBIT) could be employed if the patient is motivated to
attempt treatment (INFER). As a result of partial or com-
plete remission during the natural course of the disorder,
medication prescribed for tics in childhood may no longer be
required over time (INFER).
Recommendation 1a
Clinicians must inform patients and their caregivers about the
natural history of tic disorders (Level A).
Recommendation 1b
Clinicians must evaluate functional impairment related to tics
from the perspective of the patient and, if applicable, the
caregiver (Level A).
Recommendation 1c
Clinicians should inform patients and caregivers that watchful
waiting is an acceptable approach in people who do not ex-
perience functional impairment from their tics (Level B).
Recommendation 1d
Clinicians may prescribe CBIT as an initial treatment option
relative to watchful waiting, for people with tics who do not
experience functional impairment if they are motivated to
attempt treatment (Level C).
Recommendation 1e
Physicians prescribing medications for tics must periodically
re-evaluate the need for ongoingmedical treatment (Level A).
Psychoeducation, teacher and classroom
Rationale
TS is common, affecting approximately 1% of schoolchildren
(RELA).3 Psychoeducation about TS with peers can result in
more positive attitudes toward a person with TS, while psy-
choeducation about TS with teachers can improve knowledge
about the condition (RELA).4 Improving peers’ attitudes
about and teachers’ knowledge of TS may positively affect
people with TS (INFER).
Recommendation 2
Clinicians should refer people with TS to resources for psy-
choeducation for teachers and peers, such as the Tourette
Association of America (Level B).
Assessment and treatment of attention-
deficit/hyperactivity disorder (ADHD) in
children with tics
Rationale
Comorbid ADHD is common in people with TS, with prev-
alence ranging from 30% to 50% (RELA).5,6 Several trials
have specifically addressed the medical treatment of both
ADHD and tics in children with both disorders. This includes
trials of psychostimulants and atomoxetine, in which the aim
was to demonstrate efficacy of these treatments for ADHD
symptoms without concomitant worsening of tics. In children
with tics and ADHD, clonidine, clonidine plus methylpheni-
date, methylphenidate, and guanfacine are probably more
likely than placebo to reduce tic severity (EVID) and reduce
ADHD symptoms. In children with tics and ADHD, atom-
oxetine does not worsen tics relative to placebo (EVID) and
reduces ADHD symptoms. Comorbid ADHD is strongly
associated with functional impairment in children with TS
(RELA).7 While ADHD symptoms may improve in adoles-
cence (RELA),2 adults with TS may require ongoing care for
this comorbidity.
Recommendation 3a
Clinicians should ensure an assessment for comorbid ADHD
is performed in people with tics (Level B).
Recommendation 3b
Clinicians should evaluate the burden of ADHD symptoms in
people with tics (Level B).
Recommendation 3c
In people with tics and functionally impairing ADHD, clini-
cians should ensure appropriate ADHD treatment is provided
(Level B).
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Assessment and treatment of obsessive-
compulsive disorder (OCD) in childrenwith tics
Rationale
Obsessive-compulsive behaviors are common in people with
TS, with a comorbid diagnosis of OCD made in 10%–50%
(RELA).5,6 Subanalyses of trials of interventions for OCD in
children suggest that individuals with tics may not respond
as well as those without tics to selective serotonin reuptake
inhibitors but respond equally well to cognitive behavioral
therapy (CBT) for OCD symptoms (RELA).8,9 For this
reason, CBT is considered first-line treatment of OCD in
individuals with tic disorders (INFER).
Recommendation 4a
Clinicians should ensure an assessment for comorbid OCD is
performed in people with tics (Level B).
Recommendation 4b
In people with tics and OCD, clinicians should ensure ap-
propriate OCD treatment is provided (Level B).
Other psychiatric comorbidities
Rationale
Population-based and clinic-based studies have shown that
people with TS are at high risk of other psychiatric comorbid-
ities, including anxiety disorders, oppositional defiant disorder,
and mood disorders (RELA).5,6 Comorbid mood disorders
appear more prevalent in adolescents and adults than children
and in those with greater tic severity (RELA).6,10 A matched
case–cohort study using a national registry has shown an in-
creased risk of dying by suicide and attempting suicide in people
with TS compared with controls, which persisted after adjusting
for psychiatric comorbidity. Persistence of tics beyond young
adulthood, previous suicide attempts, and comorbid personality
disorders increased the risk of death by suicide (RELA).11
Recommendation 5a
Clinicians must ensure appropriate screening for anxiety,
mood, and disruptive behavior disorders is performed in
people with tics (Level A).
Recommendation 5b
Clinicians must inquire about suicidal thoughts and suicide
attempts in people with TS and refer to appropriate resources
if present (Level A).
Assessment of tic severity and
treatment expectations
Rationale
There are several rating scales available for measuring tic se-
verity, with the Yale Global Tic Severity Scale the most ex-
tensively deployed and validated (RELA).12 Evaluation of the
effect of treatment on tic severity in trials is measured using
such scales (EVID). The use of validated scales to measure
tic severity can aid the evaluation of treatment response in
the clinical setting (INFER). While medications, behavioral
therapy, and neurostimulation can result in meaningful re-
duction in tics (EVID), these interventions rarely result in
complete cessation of tics.
Recommendation 6a
Clinicians maymeasure tic severity using a valid scale to assess
treatment effects (Level C).
Recommendation 6b
Clinicians must counsel patients that treatments for tics in-
frequently result in complete cessation of tics (Level A).
Behavioral treatments
Rationale
People with tics receiving CBIT are more likely than those
receiving psychoeducation and supportive therapy to have
reduced tic severity (EVID). CBIT is a manualized treatment
program consisting of habit reversal training (HRT), re-
laxation training, and a functional intervention to address
situations that sustain or worsen tics (RELA).13 The child and
adult CBIT trials demonstrated the efficacy of an 8-session
protocol, though cases complicated by poor tic awareness,
treatment motivation, more severe tics, or substantial clinical
comorbidity may benefit from a longer course of therapy.
Most children (aged 9 years or older) and adults showing an
initial positive response to CBIT will maintain their treatment
gains for at least 6 months (EVID). CBIT can be effective for
children younger than 9 years, though there is little evidence
to determine efficacy in children of this age group (RELA).14
There is some evidence that the efficacy of CBIT for reducing
tics is greater for patients not concurrently taking anti-tic
medication (RELA).15 There is insufficient evidence to de-
termine the relative efficacy of HRT compared with exposure
and response prevention or educational group treatment in
reducing tic severity (EVID). There is insufficient evidence to
determine the relative efficacy of HRT by video conferencing
compared with either face-to-face HRT or wait-list control for
reducing tic severity (EVID). There is insufficient evidence to
determine the efficacy of relaxation training for reducing tic
severity (EVID). The evidence demonstrates no increased
risk of adverse effects for people treated with CBIT compared
with those treated with psychoeducation plus supportive
therapy (EVID). The effect size for CBIT appears similar to
effect sizes for medications (EVID). In light of clinician re-
sponsibility to optimally balance safety and effectiveness in
treatment decisions (PRIN), CBIT should be considered as
an initial treatment choice for tics (INFER). Given the effort
required from patients or their families, along with its benign
safety profile, CBIT is an acceptable intervention for people
with tics that lead to psychosocial or physical impairment and
who are motivated to participate in treatment (INFER).
Recommendation 7a
For people with tics who have access to CBIT, clinicians
should prescribe CBIT as an initial treatment option relative
to other psychosocial/behavioral interventions (Level B).
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Recommendation 7b
For people with tics who have access to CBIT, clinicians
should offer CBIT as an initial treatment option relative to
medication (Level B).
Recommendation 7c
Clinicians may prescribe CBIT delivered over teleconference or
secure voice over Internet protocol delivery systems if face-to-
face options are unavailable in a patient care center. If CBIT is
unavailable, other behavioral interventions for tics may be ac-
ceptable, such as exposure and response prevention (Level C).
α-Agonists for the treatment of tics
Rationale
People with tics receiving clonidine are probably more likely
than those receiving placebo to have reduced tic severity, and
people with tics receiving guanfacine are possibly more likely
than those receiving placebo to have reduced tic severity, with
the majority of trials conducted in children (EVID). In chil-
dren with tics and comorbid ADHD, clonidine and guanfacine
have demonstrated beneficial effects on both tics and ADHD
symptoms (EVID). The effect size of clonidine and guanfa-
cine on tics appears larger in children with tics and ADHD
compared with individuals with tics without a comorbid di-
agnosis of ADHD (EVID). Relative to placebo, clonidine is
probably associated with higher rates of sedation, and guan-
facine is probably associated with higher rates of drowsiness
(EVID). A systematic review of α2 adrenergic agonists for
ADHD in children and adolescents demonstrated hypoten-
sion, bradycardia, and sedation with both agents, and QTc
prolongation with guanfacine extended release (RELA).16
Abrupt withdrawal of α2 adrenergic agonists may cause re-
bound hypertension (RELA).17
Recommendation 8a
Physicians should counsel individuals with tics and comorbid
ADHD that α2 adrenergic agonists may provide benefit for
both conditions (Level B).
Recommendation 8b
Physicians should prescribe α2 adrenergic agonists for the
treatment of tics when the benefits of treatment outweigh the
risks (Level B).
Recommendation 8c
Physicians must counsel patients regarding common side
effects of α2 adrenergic agonists, including sedation (Level A).
Recommendation 8d
Physicians must monitor heart rate and blood pressure in
patients with tics treated with α2 adrenergic agonists (Level A).
Recommendation 8e
Physicians prescribing guanfacine extended release must
monitor the QTc interval in patients with a history of cardiac
conditions, patients taking other QT-prolonging agents, or
patients with a family history of long QT syndrome (Level A).
Recommendation 8f
Physicians discontinuing α2 adrenergic agonists must gradu-
ally taper them to avoid rebound hypertension (Level A).
Antipsychotic treatment for tics
Rationale
Haloperidol, risperidone, aripiprazole, and tiapride are proba-
bly more likely than placebo to reduce tic severity (EVID), and
pimozide, ziprasidone, and metoclopramide are possibly more
likely than placebo to reduce tic severity (EVID). There is
insufficient evidence to determine the relative efficacy of these
drugs (EVID). Relative to placebo, the evidence demonstrates
a higher risk of drug-induced movement disorders with halo-
peridol, pimozide, and risperidone (EVID), a higher risk of
weight gain with risperidone and aripiprazole (EVID), a higher
risk of somnolence with risperidone, aripiprazole, and tiapride
(EVID), a higher risk of QT prolongation with pimozide
(EVID), and a higher risk of elevated prolactin with haloperi-
dol, pimozide, and metoclopramide (EVID). Systematic
reviews of trials and cohort studies demonstrate a higher risk of
drug-induced movement disorders (including tardive dyski-
nesia, drug-induced parkinsonism, akathisia, acute dystonia,
and tardive dystonia), weight gain, adverse metabolic side
effects, prolactin increase, and QT prolongation with both first-
and second-generation antipsychotics across psychiatric and
neurologic conditions (RELA).18,19 The long-term use of
metoclopramide is associated with tardive dyskinesia, resulting
in a black box warning from the US Food and Drug Admin-
istration.20 The relative propensity for these adverse effects
varies by agent and is often dose-dependent (RELA). Physi-
cians have a duty to monitor the effectiveness and safety of
prescribed medications (PRIN), and evidence-based moni-
toring protocols are available.21 Abrupt discontinuation of an-
tipsychotic medications can cause withdrawal dyskinesias
(RELA).22,23
Recommendation 9a
Physicians may prescribe antipsychotics for the treatment of
tics when the benefits of treatment outweigh the risks
(Level C).
Recommendation 9b
Physicians must counsel patients on the relative propensity of
antipsychotics for extrapyramidal, hormonal, and metabolic
adverse effects to inform decision-making on which antipsy-
chotic should be prescribed (Level A).
Recommendation 9c
Physicians prescribing antipsychotics for tics must prescribe
the lowest effective dose to decrease the risk of adverse effects
(Level A).
Recommendation 9d
Physicians prescribing antipsychotics for tics should monitor
for drug-induced movement disorders and for metabolic and
hormonal adverse effects of antipsychotics, using evidence-
based monitoring protocols (Level B).
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Recommendation 9e
Physicians prescribing antipsychotics for tics must perform
electrocardiography and measure the QTc interval before and
after starting pimozide or ziprasidone, or if antipsychotics are
coadministered with other drugs that can prolong the QT in-
terval (Level A).
Recommendation 9f
When attempting to discontinue antipsychotics for tics,
physicians should gradually taper medications over weeks to
months to avoid withdrawal dyskinesias (Level B).
Botulinum toxin injections for tics
Botulinum toxin injections with onabotulinumtoxinA are
probably more likely than placebo to reduce tic severity in
adolescents and adults (EVID). Premonitory urges may also be
improved by botulinum toxin injections (RELA).24 Relative to
placebo, onabotulinumtoxinA is associated with higher rates of
weakness (EVID). Hypophonia is a common side effect of
botulinum toxin injections in the laryngeal muscles for vocal tics
(RELA).25 The effects of botulinum toxin injections last 12–16
weeks, after which treatment needs to be repeated (PRIN).
Recommendation 10a
Physicians may prescribe botulinum toxin injections for the
treatment of adolescents and adults with localized and both-
ersome simple motor tics when the benefits of treatment
outweigh the risks (Level C).
Recommendation 10b
Physicians may prescribe botulinum toxin injections for the
treatment of older adolescents and adults with severely dis-
abling or aggressive vocal tics when the benefits of treatment
outweigh the risks (Level C).
Recommendation 10c
Physicians must counsel individuals with tics that botulinum
toxin injections may cause weakness and hypophonia, and
that all effects are temporary (Level A).
Topiramate for the treatment of tics
Rationale
Topiramate is possibly more likely than placebo to reduce tic
severity (EVID). In patients with mild but troublesome tics
who are not obtaining a satisfactory response or experience
adverse effects from other treatments, topiramate may be
a useful alternative. While generally well-tolerated at low doses
(25–150 mg/day) it may cause adverse effects, including cog-
nitive and language problems, somnolence, and weight loss,
and may increase the risk of renal stones (RELA).26–28
Recommendation 11a
Physicians should prescribe topiramate for the treatment of tics
when the benefits of treatment outweigh the risks (Level B).
Recommendation 11b
Physicians must counsel patients regarding common adverse
effects of topiramate, including cognitive and language problems,
somnolence, weight loss, and an increased risk of renal stones
(Level A).
Cannabis-basedmedications for the treatment
of patients with TS
Rationale
Some patients with TS use cannabis as a self-medication for
tics and comorbidities (RELA).29 There is limited evidence
that δ-9-tetrahydrocannabinol (THC), dronabinol, is possibly
more likely than placebo to reduce tic severity in adults with
TS (EVID). There is insufficient evidence to determine
whether the efficacy of nabiximols, nabilone, and cannabidiol
(CBD), as well as different strains of medicinal cannabis—
standardized for different levels of THC and CBD—is similar
to THC. Compared with placebo, cannabis-based medi-
cations are associated with increased risk of short-term ad-
verse events, most commonly dizziness, dry mouth, and
fatigue (RELA).30 There is no evidence that controlled
treatment with cannabis-based medication may induce ad-
diction to cannabinoids. Acute withdrawal of cannabinoids is
generally safe and well-tolerated without significant adverse
events (RELA).30,31 Cannabis-based medications should be
avoided in children and adolescents, not only due to a paucity
of evidence but due to the association between cannabis ex-
posure in adolescence and potentially harmful cognitive and
affective outcomes in adulthood (RELA, PRIN).32 Cannabis-
based medication should not be used in women who are
pregnant or breastfeeding or in patients with psychosis
(PRIN). Prescription of and access to medical marijuana
varies by region; practitioners must abide by regional legis-
lation on the use of medical marijuana (PRIN).
Recommendation 12a
Due to the risks associated with cannabis use and widespread
self-medication with cannabis for tics, where regional legis-
lation and resources allow, physicians must offer to direct
patients to appropriate medical supervision when cannabis is
used as self-medication for tics (Level A). Appropriate med-
ical supervision would entail education and monitoring for
efficacy and adverse effects.
Recommendation 12b
Where regional legislation allows, physicians may consider
treatment with cannabis-based medication in otherwise
treatment-resistant adults with clinically relevant tics (Level C).
Recommendation 12c
Where regional legislation allows, physicians may consider
treatment with cannabis-based medication in adults with
TS who already use cannabis efficiently as a self-medication
in order to better control and improve quality of treatment
(Level C).
Recommendation 12d
Where regional legislation allows, physicians prescribing
cannabis-based medication must prescribe the lowest effective
dose to decrease the risk of adverse effects (Level A).
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Recommendation 12e
Physicians prescribing cannabis-based medication must inform
patients that medication may impair driving ability (Level A).
Recommendation 12f
Physicians prescribing cannabis-based medication to patients
with TS must periodically reevaluate the need for ongoing
treatment (Level A).
Deep brain stimulation (DBS) for tics in the
setting of TS
Rationale
Patients with severe TS, resistant to medical and behavioral
therapy, may benefit from the application of DBS. An important
challenge and limitation in the evaluation of the evidence
around DBS in TS is that, even in expert DBS centers, few
operations per year are performed. Furthermore, there is limited
information from randomized clinical trials for analysis and in-
terpretation. There is no consensus on the optimal brain target
for the treatment of tics, but the following regions have been
stimulated in patients with TS: the centromedian thalamus, the
globus pallidus internus (ventral and dorsal), the globus pallidus
externus, the subthalamic nucleus, and the ventral striatum/
ventral capsular nucleus accumbens region. DBS of the ante-
romedial globus pallidus is probably more likely than sham
stimulation to reduce tic severity (EVID). There is insufficient
evidence to determine the efficacy ofDBS of the thalamus or the
centromedian-parafascicular complex region of the thalamus in
reducing tic severity (EVID). Complications of treatment, in-
cluding infection and removal of hardware, appear more com-
mon with TS (EVID) than with other neurologic conditions.
Recommendations from the Movement Disorders Society
suggest that, when DBS is used in TS, best practices used for
other DBS applications are followed, including confirmation
of diagnosis, use of multidisciplinary screening, and stabili-
zation of psychiatric comorbidities inclusive of active suici-
dality (RELA).33 Appropriate patient selection is one of the
most important predictors of success of DBS treatment,
making multidisciplinary evaluation essential (RELA).34 Be-
cause of the complexity of the patient population, centers
performing DBS have been encouraged to screen candidates
preoperatively and to follow them postoperatively. There has
been concern about high risk of suicide and other negative
psychiatric sequelae in patients with TS not screened and
monitored for depression, anxiety, and bipolar tendencies.
The largest available randomized trials of DBS have revealed
benefits on motor and phonic tics for the ventral globus
pallidus internus and the centromedian thalamic region tar-
get; however, these studies have raised methodologic con-
cerns that need to be addressed in future trials (RELA).35
There is little information on the effects of DBS on psychiatric
comorbidities and on the efficacy of DBS in children with TS.
Recommendation 13a
Physicians must use a multidisciplinary evaluation (psychia-
trist or neurologist, neurosurgeon, and neuropsychologist) to
establish when the benefits of treatment outweigh the risks of
prescribing DBS for medication-resistant motor and phonic
tics (Level A).
Recommendation 13b
Physicians should confirm the DSM-5 diagnosis of TS and
exclude secondary and functional tic-like movements when
considering DBS for medication-resistant tics (Level B).
Recommendation 13c
A mental health professional must screen patients pre-
operatively and follow patients postoperatively for psychiatric
disorders that may impede the long-term success of the
therapy (Level A).
Recommendation 13d
Physicians must confirm that multiple classes of medication
(antipsychotics, dopamine depleters, α2 agonists) and be-
havioral therapy have been administered (or are contra-
indicated) before prescribing DBS for tics (Level A).
Recommendation 13e
Physiciansmay considerDBS for severe, self-injurious tics, such
as severe cervical tics that result in spinal injury (Level C).
Suggestions for future research
1. Future research on behavioral interventions for tics
should include comparisons of the relative efficacy of
CBIT vs pharmacotherapy. Additional research should
be conducted on treatment sequencing and decision-
making and for whom particular sequences of treatment
are most effective. Further research should continue to
test the efficacy of other behavioral treatments, including
exposure and response prevention, mindfulness-based
treatments, or more global tic-related interventions.36 As
the evidence is insufficient at present to conclude that
CBIT delivered by teleconference is as effective as face-
to-face treatment, further well-designed studies with
adequate sample sizes are needed to establish non-
inferiority. Additional work to more accurately charac-
terize the neurocognitive and behavioral mechanism of
action underlying CBIT will be necessary to enhance the
overall effectiveness and inform patient–treatment
matching algorithms.37
2. Future research on medications for tics should include
noninferiority trials of agents commonly used for the
treatment of tics for which limited evidence from
randomized controlled trials is available. Agents for
which evidence is promising but limited include the
first-generation antipsychotic fluphenazine.38–40 Trials
are currently underway with the selective D1 antagonist
ecopipam and evidence on the efficacy of this drug is
expected soon.
3. The dopamine depleters, tetrabenazine, deutetrabenazine,
and valbenazine, act by blocking vesicular monoamine
transporter type 2 (VMAT2). Although no randomized
controlled trials have been published with the VMAT2
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inhibitors in the treatment of tics, these drugs are
increasingly used off-label. When appropriately dosed,
these drugs are generally well-tolerated but may be
associated with drowsiness, depression, and parkinson-
ism. Although an initial phase II trial of valbenazine did
not reach the primary endpoint in adults and children
with TS, this was thought to be due to underdosing.
Further and better-designed trials are currently un-
derway with valbenazine and deutetrabenazine for the
treatment of tics.41–43
4. Our systematic review included 3 different traditional
Chinese medicine products: the 5-Ling granule,44 the
Ningdong granule formulated by Zhao,45 and the
Ningdong granule formulated by Wang.46 We did not
make formal recommendations for or against the use of
these compounds, all of which reported superiority over
placebo. Our panel had concerns about the inclusion
criteria for the 5-Ling granule study, as participants also
had a condition fitting the “excessive subtype” in
traditional Chinese medicine–based diagnosis (see full
and unabridged practice guideline for full details), with
no equivalent diagnosis in Western medicine or clear
understanding of pathophysiology. Furthermore, this
study excluded children with the 2 most common
comorbidities seen with TS: ADHD andOCD. There are
therefore concerns with respect to the generalizability of
these findings. Finally, the availability of these com-
pounds outside of the trials is unknown and safety
concerns remain regarding the ingredients—the Ning-
dong granule formulated by Wang contains human dried
placenta. Further research and information on the safety
and reliability of production of these agents is required
before formal recommendations can be made.
5. There is a need for more long-term studies of drug
efficacy and adverse effects as well as the efficacy and
safety of medication combinations for severe tics resistant
to monotherapy.
6. Few studies have been performed investigating the
efficacy and safety of cannabis-based medicine in children
with various diseases. Recently it was reported that CBD
may significantly reduce convulsive seizure frequency in
children with Dravet syndrome.47 There is preliminary
evidence that THC might also be effective in children for
vomiting due to antineoplastic treatment48,49 and in
treatment-resistant spasticity.50 There is increasing
evidence that cannabis-based medicine might be effective
in adults with TS.51 A recent press release for a single-
dose study of a first-in-class small molecule inhibitor of
monoacylglycerol lipase, ABX-1431, which regulates one
of the key natural activators of the central cannabinoid
CB1 receptor, suggests efficacy for the treatment of tics.52
7. Case reports and case series have comprised the majority
of the outcomes data on the efficacy of DBS for TS. An
international DBS registry53 has been developed to
collect data on DBS outcomes in patients with TS
implanted in various centers. The registry also collects
information about response to nonstandardized selection
criteria, various brain targets, differences in hardware, and
variability in the programming parameters used. The goal
of future research on DBS in TS should be to improve
outcomes and quality of life by conducting well-designed
multicenter studies, share data across centers, uncover
best practices, and provide critical information to
regulatory agencies that will lead to approval of DBS in
TS. There are important limitations to the currently
available trials using DBS in TS. The uncertainty in
optimal target and the individual variability in pro-
gramming and management between participants make
trials challenging. Recent research on DBS in TS has
revealed the intriguing possibility that it may not be
necessary to have the devices activated continuously as
has been the standard for other movement disorders.
Moreover, adaptive closed-loop DBS is being explored in
an ongoing clinical trial.
8. Future research on the effect of special diets, nutritional
supplements, and exercise on tic severity is needed.
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